|Positive WB detected in
|RAW 264.7 cells, Jurkat cells, HepG2 cells, COLO 320 cells, HeLa cells, C6 cells, NIH/3T3 cells, Raji cells
|Positive IHC detected in
|human pancreas cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Western Blot (WB)
|WB : 1:500-1:2000
|IHC : 1:20-1:200
|It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
|Sample-dependent, check data in validation data gallery
10037-1-Ig targets XIAP in WB, IHC, ELISA applications and shows reactivity with human, rat, mouse samples.
|human, rat, mouse
|Host / Isotype
|Rabbit / IgG
|XIAP fusion protein Ag0022
|X-linked inhibitor of apoptosis
|Calculated molecular weight
|Observed molecular weight
|GenBank accession number
|Gene ID (NCBI)
|Protein A purification
|PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
|Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.
XIAP, also named as API3, BIRC4 and IAP3, belongs to the IAP family. It has E3 ubiquitin-protein ligase activity. It mediates the proteasomal degradation of target proteins, such as caspase-3, SMAC or AIFM1. XIAP is an inhibitor of caspase-3, -7 and -9. It mediates activation of MAP3K7/TAK1, leading to the activation of NF-kappa-B. XIAP is an apoptotic suppressor. It is ubiquitinated and degraded by the proteasome in apoptotic cells. The MW of XIAP is 45-56 kDa.
Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer.
DAB2IP is a bifunctional tumor suppressor that regulates wildtype RAS and inflammatory cascades in KRAS mutant colon cancer
An ATM/TRIM37/NEMO axis counteracts genotoxicity by activating nuclear-to-cytoplasmic NF-κB signaling.
Acta Pharmacol Sin
Aspirin modulates succinylation of PGAM1K99 to restrict the glycolysis through NF-κB/HAT1/PGAM1 signaling in liver cancer.
Int J Nanomedicine
Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity.
CRNDE affects the malignant biological characteristics of human glioma stem cells by negatively regulating miR-186.